StockNews.com Begins Coverage on Athersys (NASDAQ:ATHX)

Stock analysts at StockNews.com started coverage on shares of Athersys (NASDAQ:ATHX) in a note issued to investors on Saturday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

Athersys Price Performance

The firm has a market cap of $833,000.00, a P/E ratio of 0.00 and a beta of -0.90. Athersys has a 52-week low of $0.01 and a 52-week high of $1.99.

Athersys Company Profile

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.